Keratoconus Emerging drugs and Key Players | DelveInsight

September 08 17:01 2020
Keratoconus Emerging drugs and Key Players | DelveInsight

DelveInsight Business Research LLP
Keratoconus Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Keratoconus market. A detailed picture of the Keratoconus pipeline landscape is provided, which includes the disease overview and Keratoconus treatment guidelines.

Keratoconus is an eye disorder characterized by progressive thinning and changes in the shape of the cornea.

The pipeline of KC possess only one key player, which is iVeena Delivery Systems. The dynamics of KC market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapy is expected during the forecast period of 2020-2030.

IVMED-80 is the first twice-daily, eye-drop, non-surgical, non-UV light treatment for medical crosslinking of the cornea being developed by iVeena Delivery Systems. The drug, with its copper-based formulation, is reportedly the first eye drop designed to treat KC without the need for adjunctive laser treatment or surgical intervention. IVMED-80’s mechanism of action centers on enhancing the activity of lysyl oxidase (LOX) – the enzyme responsible for corneal collagen crosslinking, and also known to be associated with KC and copper, which is a co-factor of LOX, is the active ingredient of the drug. The FDA granted orphan drug designation for IVMED-80 for the treatment of KC. In February 2019, the company announced the commencement of a 36 patient phase I/IIa pilot clinical study for the treatment of mild and moderate KC (IVMED-80) and presented an abstract of the trial in the 2020 ARVO Annual Meeting. Final results of the trial are expected at the end of August 2020. Currently, this therapy is in phase I/II a clinical developmental trial for mild and moderate form of KC.

Keratoconus Marketed therapies

  1. Photrexa Viscous and Photrexa: Glaukos/Avedro
  2. CE Marked Riboflavin Formulations: Avedro/ Glaukos Corporation
  3. Ricrolin: Sooft Italia
  4. Collagex Riboflavin: Lightmed_OptiMed
  5. Peschke Riboflavin Solutions: Peschke Meditrade GmbH

Keratoconus Emerging Therapies

IVMED-80: iVeena Delivery Systems

 

Request for sample pages
Table of contents

1. Report Introduction

2. Keratoconus 

2.1. Overview

2.2. History 

2.3. Keratoconus Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Keratoconus Diagnosis 

2.6.1. Diagnostic Guidelines

3. Keratoconus Current Treatment Patterns

3.1. Keratoconus Treatment Guidelines

4. Keratoconus – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Keratoconus companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Keratoconus Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Keratoconus Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Keratoconus Late Stage Products (Phase-III)

7. Keratoconus Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Keratoconus Discontinued Products

13. Keratoconus Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Keratoconus Key Companies

15. Keratoconus Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Keratoconus Unmet Needs

18. Keratoconus Future Perspectives

19. Keratoconus Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/kolkatanewstoday/jharkhandmagazine.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7